{"id":"lpv","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":"20-30","effect":"Lipid abnormalities (elevated cholesterol/triglycerides)"},{"rate":"2-5","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lopinavir (LPV) is a potent inhibitor of the HIV-1 protease enzyme, which is essential for cleaving viral polyproteins into functional components during HIV replication. By inhibiting this protease, LPV prevents the production of infectious viral particles, thereby suppressing HIV replication and reducing viral load in infected individuals. It is typically administered as a fixed-dose combination with ritonavir (a CYP3A4 inhibitor) to enhance lopinavir bioavailability.","oneSentence":"LPV is a protease inhibitor that blocks HIV protease, preventing the maturation of HIV virions and reducing viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:41.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"},{"name":"COVID-19 (investigational use in phase 3)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02369406","phase":"PHASE2, PHASE3","title":"Early Infant HIV Treatment in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2015-05-04","conditions":"HIV, Pediatric AIDS","enrollment":67},{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT07326215","phase":"NA","title":"A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+","status":"RECRUITING","sponsor":"Vantive Health LLC","startDate":"2025-12-11","conditions":"Acute Respiratory Distress Syndrome, Acute Kidney Injury","enrollment":99},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT02140255","phase":"PHASE1, PHASE2","title":"Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-23","conditions":"HIV Infection","enrollment":1120},{"nctId":"NCT07095959","phase":"NA","title":"Marshall Vein Ethanol Infusion in Addition to Pulsed Electric Field Ablation Versus Pulsed Electric Field Ablation Alone for Paroxysmal Atrial Fibrillation","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-07-31","conditions":"Atrial Fibrillation (AF)","enrollment":340},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT06895148","phase":"NA","title":"ADHERE-LPV Advancing Delivery of High-Quality Evidence-Based Respiratory Efforts in Lung-Protective Ventilation","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-07-01","conditions":"Ventilation","enrollment":1125},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT01513122","phase":"PHASE4","title":"Bone and Body Comp: A Sub Study of the SECOND-LINE Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2010-02","conditions":"HIV","enrollment":210},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00866021","phase":"PHASE4","title":"Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-02","conditions":"HIV/HCV Co-infection, HIV Infections","enrollment":68},{"nctId":"NCT04487145","phase":"PHASE4","title":"Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-11-23","conditions":"Drug-Drug Interaction, HIV Infection","enrollment":194},{"nctId":"NCT05831683","phase":"","title":"Standard Operating Procedure As a Valuable Tool to Increase Adherence to Lung Protective Ventilation Among Anesthesiologists.","status":"COMPLETED","sponsor":"Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.","startDate":"2023-04-20","conditions":"Adherence, Treatment","enrollment":164},{"nctId":"NCT05426421","phase":"","title":"Tolerability of Lopinavir Versus Dolutegravir for Children and Adolescents Living With HIV","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2022-07-11","conditions":"HIV","enrollment":258},{"nctId":"NCT04466241","phase":"PHASE2, PHASE3","title":"Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-11-27","conditions":"COVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":294},{"nctId":"NCT01614405","phase":"NA","title":"Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2012-06","conditions":"Primary Biliary Cirrhosis","enrollment":13},{"nctId":"NCT01717885","phase":"","title":"Antimalarial Pharmacology in Children and Pregnant Women in Uganda","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-08","conditions":"Malaria, HIV","enrollment":473},{"nctId":"NCT01854762","phase":"PHASE2, PHASE3","title":"Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection","status":"TERMINATED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2015-06-01","conditions":"HIV, Pregnancy","enrollment":33},{"nctId":"NCT04663802","phase":"NA","title":"Implementation of Nudges to Promote Utilization of Low Tidal Volume Ventilation (INPUT) Study","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-02-22","conditions":"ARDS, Critical Illness, Acute Respiratory Distress Syndrome","enrollment":7342},{"nctId":"NCT04744298","phase":"NA","title":"Identification and Treatment of Hypoxemic Respiratory Failure and ARDS With Protection, Paralysis, and Proning Pathway","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2021-04-01","conditions":"Acute Respiratory Distress Syndrome, Hypoxemic Respiratory Failure, ARDS, Human","enrollment":19916},{"nctId":"NCT00056641","phase":"PHASE2","title":"Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02-18","conditions":"HIV Infections","enrollment":328},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT04070053","phase":"NA","title":"Treatment of Hypoxemic Respiratory Failure and ARDS With Protection, Paralysis, and Proning (TheraPPP) Pathway","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2019-08-23","conditions":"Acute Respiratory Distress Syndrome, Hypoxemic Respiratory Failure, ARDS, Human","enrollment":920},{"nctId":"NCT02227238","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-11","conditions":"HIV Infections","enrollment":627},{"nctId":"NCT04328285","phase":"PHASE3","title":"Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2020-04-14","conditions":"COVID-19","enrollment":118},{"nctId":"NCT04499677","phase":"PHASE2","title":"FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-09-24","conditions":"COVID-19","enrollment":240},{"nctId":"NCT02712801","phase":"PHASE4","title":"Antiretroviral Regime for Viral Eradication in Newborns","status":"COMPLETED","sponsor":"National Center for Women and Children's Health, China CDC","startDate":"2016-04","conditions":"HIV/AIDS and Infections","enrollment":600},{"nctId":"NCT03603977","phase":"","title":"Simplified Treatment of Anti-retrovirus in China (C-STAR)","status":"RECRUITING","sponsor":"Guangzhou 8th People's Hospital","startDate":"2017-11-01","conditions":"HIV/AIDS","enrollment":600},{"nctId":"NCT04354428","phase":"PHASE2, PHASE3","title":"Treatment for COVID-19 in High-Risk Adult Outpatients","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-04-16","conditions":"COVID-19, SARS-CoV-2","enrollment":289},{"nctId":"NCT00145795","phase":"PHASE4","title":"A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2004-04","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT05017558","phase":"","title":"Evaluation of Measurement of Maternal Viral Load at Delivery to Optimise Post-natal Prophylaxis of HIV-exposed Newborns","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-03","conditions":"Mother to Child HIV Transmission","enrollment":100},{"nctId":"NCT01061151","phase":"PHASE3","title":"Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03-01","conditions":"HIV Infections","enrollment":3747},{"nctId":"NCT04321174","phase":"PHASE3","title":"COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2020-04-17","conditions":"Coronavirus Infections, Post-exposure Prophylaxis","enrollment":123},{"nctId":"NCT00109590","phase":"PHASE2","title":"Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":175},{"nctId":"NCT01571414","phase":"PHASE1","title":"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05","conditions":"Tuberculosis","enrollment":52},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT01172535","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-11","conditions":"HIV","enrollment":97},{"nctId":"NCT00084149","phase":"PHASE2","title":"Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-02","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00270296","phase":"PHASE2","title":"Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":730},{"nctId":"NCT00004855","phase":"NA","title":"Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT01511237","phase":"PHASE3","title":"Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2011-12","conditions":"HIV Infections","enrollment":379},{"nctId":"NCT02369965","phase":"PHASE3","title":"Test Albuvirtide in Experienced Patients","status":"COMPLETED","sponsor":"Frontier Biotechnologies Inc.","startDate":"2014-02-19","conditions":"HIV Infections, AIDS","enrollment":418},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01818258","phase":"PHASE4","title":"IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-10-26","conditions":"HIV Positive, Malnourished","enrollment":52},{"nctId":"NCT02383849","phase":"","title":"IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-08-04","conditions":"Low-Birth-Weight Infant, Tuberculosis, HIV","enrollment":124},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT04138199","phase":"","title":"A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation","status":"TERMINATED","sponsor":"AbbVie","startDate":"2019-11-01","conditions":"HIV-1 Infection","enrollment":239},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT02431975","phase":"PHASE4","title":"Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-08","conditions":"HIV","enrollment":73},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT01138202","phase":"PHASE2","title":"Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-11","conditions":"HIV Infections, Tuberculosis","enrollment":40},{"nctId":"NCT00887120","phase":"PHASE2","title":"Dose Reduction of Lopinavir in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00627055","phase":"PHASE4","title":"Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-05","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT01159275","phase":"PHASE1, PHASE2","title":"Lopinavir (LPV) Dose Reduction","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2009-07","conditions":"HIV-1 Infections","enrollment":20},{"nctId":"NCT00281606","phase":"PHASE4","title":"A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2006-02-14","conditions":"HIV Infection","enrollment":65},{"nctId":"NCT03698799","phase":"","title":"Adherence to LPV in SICU and Associated Clinical Outcomes","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2018-04-09","conditions":"Adult, Guideline Adherence, Humans","enrollment":306},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02415985","phase":"PHASE2","title":"Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2015-06","conditions":"HIV, Tuberculosis","enrollment":40},{"nctId":"NCT04192305","phase":"","title":"Impact of LPV During OFA on Postoperative Oxygen Saturation.","status":"UNKNOWN","sponsor":"AZ Sint-Jan AV","startDate":"2019-12-01","conditions":"Oxygen Saturation","enrollment":100},{"nctId":"NCT01116817","phase":"PHASE4","title":"Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2010-08","conditions":"HIV","enrollment":35},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT03660306","phase":"","title":"Impact of OFA During LPV on Postoperative Oxygen Saturation","status":"COMPLETED","sponsor":"AZ Sint-Jan AV","startDate":"2018-08-01","conditions":"Decreased Lung Compliance, Oxygen Requirement","enrollment":64},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT03197337","phase":"NA","title":"Is Localized Provoked Vulvodynia Caused by Laxity of the Utero-Sacral Ligaments?","status":"COMPLETED","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2017-07-23","conditions":"Vulvodynia, Referred Pain","enrollment":17},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120},{"nctId":"NCT01632891","phase":"PHASE1, PHASE2","title":"Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-01-10","conditions":"HIV-1 Infection, Pf Subclinical Parasitemia","enrollment":52},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT03836833","phase":"PHASE1, PHASE2","title":"Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation","status":"UNKNOWN","sponsor":"Drugs for Neglected Diseases","startDate":"2019-06-04","conditions":"HIV","enrollment":50},{"nctId":"NCT02581202","phase":"","title":"The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-21","conditions":"HIV-1 Infection","enrollment":216},{"nctId":"NCT02346487","phase":"PHASE3","title":"Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2015-09","conditions":"HIV","enrollment":1003},{"nctId":"NCT00993031","phase":"PHASE3","title":"Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-12-15","conditions":"Malaria, HIV Infections","enrollment":389},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT03868319","phase":"NA","title":"Lung-protective Ventilation During Robot-assisted Laparoscopic Radical Cystectomy","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2017-01-01","conditions":"Lung-protective Ventilation","enrollment":258},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT03314064","phase":"PHASE4","title":"Phase 4 Study of Dolutegravir (DTG) in Russian Federation","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-12-08","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":43},{"nctId":"NCT00978068","phase":"PHASE3","title":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-09","conditions":"Malaria, HIV Infections","enrollment":176},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00608569","phase":"NA","title":"Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-03","conditions":"HIV Infections","enrollment":529},{"nctId":"NCT00089505","phase":"PHASE3","title":"NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2006-11","conditions":"HIV Infections","enrollment":745},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00531986","phase":"PHASE4","title":"HIV - Monotherapy in Switzerland (MOST-ch)","status":"TERMINATED","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2007-01","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT02671383","phase":"PHASE3","title":"Evaluation of Low-dose Darunavir in a Switch Study","status":"COMPLETED","sponsor":"Willem Daniel Francois Venter","startDate":"2016-06-30","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT02231281","phase":"PHASE3","title":"Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults","status":"UNKNOWN","sponsor":"Yongtao Sun, MD, PhD","startDate":"2014-08","conditions":"Acute HIV Infection","enrollment":65},{"nctId":"NCT00357552","phase":"NA","title":"Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2008-01","conditions":"HIV Infections","enrollment":123},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT01662336","phase":"","title":"Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-06","conditions":"Human Immunodeficiency Virus Infection","enrollment":173},{"nctId":"NCT01637558","phase":"PHASE4","title":"Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2012-11","conditions":"Tuberculosis, HIV","enrollment":200},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT01905059","phase":"PHASE3","title":"Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-02","conditions":"HIV Infection","enrollment":265},{"nctId":"NCT01003990","phase":"PHASE3","title":"Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-10","conditions":"HIV","enrollment":710},{"nctId":"NCT02348177","phase":"PHASE4","title":"Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2013-01","conditions":"Acquired Immunodeficiency Syndrome, Tuberculosis","enrollment":96},{"nctId":"NCT00307151","phase":"PHASE2","title":"Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2005-12","conditions":"HIV Infections","enrollment":452}],"_emaApprovals":[],"_faersSignals":[{"count":20,"reaction":"MATERNAL DRUGS AFFECTING FOETUS"},{"count":10,"reaction":"EXPOSURE DURING PREGNANCY"},{"count":8,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"},{"count":6,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"},{"count":5,"reaction":"ABORTION INDUCED"},{"count":5,"reaction":"PREMATURE RUPTURE OF MEMBRANES"},{"count":4,"reaction":"ABORTION SPONTANEOUS"},{"count":4,"reaction":"CONGENITAL ANOMALY"},{"count":4,"reaction":"NEURAL TUBE DEFECT"},{"count":4,"reaction":"PLAGIOCEPHALY"}],"_approvalHistory":[],"publicationCount":1639,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LPV","genericName":"LPV","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LPV is a protease inhibitor that blocks HIV protease, preventing the maturation of HIV virions and reducing viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}